USCMA Revision Worsens Innovator Woes In Canada
News Comes As Consultation On New Pricing Guidelines Is Extended
Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
